Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.24
MDSO's Cash to Debt is ranked lower than
70% of the 1865 Companies
in the Global Health Information Services industry.

( Industry Median: 11.22 vs. MDSO: 1.24 )
Ranked among companies with meaningful Cash to Debt only.
MDSO' s Cash to Debt Range Over the Past 10 Years
Min: 0.4  Med: 64.92 Max: No Debt
Current: 1.24
Equity to Asset 0.44
MDSO's Equity to Asset is ranked lower than
71% of the 1764 Companies
in the Global Health Information Services industry.

( Industry Median: 0.60 vs. MDSO: 0.44 )
Ranked among companies with meaningful Equity to Asset only.
MDSO' s Equity to Asset Range Over the Past 10 Years
Min: -1.75  Med: 0.41 Max: 0.67
Current: 0.44
-1.75
0.67
Interest Coverage 2.33
MDSO's Interest Coverage is ranked lower than
91% of the 1274 Companies
in the Global Health Information Services industry.

( Industry Median: 60.06 vs. MDSO: 2.33 )
Ranked among companies with meaningful Interest Coverage only.
MDSO' s Interest Coverage Range Over the Past 10 Years
Min: 1.31  Med: 51.54 Max: 9999.99
Current: 2.33
1.31
9999.99
F-Score: 8
Z-Score: 6.08
M-Score: -2.95
WACC vs ROIC
12.70%
13.87%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 9.16
MDSO's Operating margin (%) is ranked higher than
67% of the 1810 Companies
in the Global Health Information Services industry.

( Industry Median: 4.89 vs. MDSO: 9.16 )
Ranked among companies with meaningful Operating margin (%) only.
MDSO' s Operating margin (%) Range Over the Past 10 Years
Min: -36.17  Med: 7.45 Max: 14
Current: 9.16
-36.17
14
Net-margin (%) 5.29
MDSO's Net-margin (%) is ranked higher than
61% of the 1810 Companies
in the Global Health Information Services industry.

( Industry Median: 3.19 vs. MDSO: 5.29 )
Ranked among companies with meaningful Net-margin (%) only.
MDSO' s Net-margin (%) Range Over the Past 10 Years
Min: -52.41  Med: 3.52 Max: 21.36
Current: 5.29
-52.41
21.36
ROE (%) 7.51
MDSO's ROE (%) is ranked higher than
56% of the 1757 Companies
in the Global Health Information Services industry.

( Industry Median: 5.50 vs. MDSO: 7.51 )
Ranked among companies with meaningful ROE (%) only.
MDSO' s ROE (%) Range Over the Past 10 Years
Min: 2.48  Med: 11.85 Max: 63.95
Current: 7.51
2.48
63.95
ROA (%) 3.25
MDSO's ROA (%) is ranked higher than
53% of the 1863 Companies
in the Global Health Information Services industry.

( Industry Median: 2.73 vs. MDSO: 3.25 )
Ranked among companies with meaningful ROA (%) only.
MDSO' s ROA (%) Range Over the Past 10 Years
Min: -106.4  Med: 4.18 Max: 22.66
Current: 3.25
-106.4
22.66
ROC (Joel Greenblatt) (%) 85.26
MDSO's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 1830 Companies
in the Global Health Information Services industry.

( Industry Median: 21.22 vs. MDSO: 85.26 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MDSO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -318.3  Med: 71.34 Max: 277.92
Current: 85.26
-318.3
277.92
Revenue Growth (3Y)(%) 17.40
MDSO's Revenue Growth (3Y)(%) is ranked higher than
80% of the 1441 Companies
in the Global Health Information Services industry.

( Industry Median: 4.90 vs. MDSO: 17.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MDSO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -21.7  Med: 8.20 Max: 17.5
Current: 17.4
-21.7
17.5
EBITDA Growth (3Y)(%) 2.20
MDSO's EBITDA Growth (3Y)(%) is ranked lower than
59% of the 1170 Companies
in the Global Health Information Services industry.

( Industry Median: 7.70 vs. MDSO: 2.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MDSO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -2.30 Max: 14.7
Current: 2.2
0
14.7
EPS Growth (3Y)(%) -13.10
MDSO's EPS Growth (3Y)(%) is ranked lower than
73% of the 1068 Companies
in the Global Health Information Services industry.

( Industry Median: 7.50 vs. MDSO: -13.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MDSO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -48.4  Med: -13.20 Max: 40.9
Current: -13.1
-48.4
40.9
» MDSO's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-27)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

MDSO Guru Trades in Q2 2015

Jim Simons 16,294 sh (New)
Paul Tudor Jones 4,672 sh (New)
Frank Sands 5,576,577 sh (+3.27%)
Joel Greenblatt Sold Out
Columbia Wanger 1,945,061 sh (-3.17%)
Chuck Royce 160,465 sh (-3.78%)
Ron Baron 122,944 sh (-16.56%)
» More
Q3 2015

MDSO Guru Trades in Q3 2015

Jim Simons 54,194 sh (+232.60%)
Columbia Wanger 1,955,759 sh (+0.55%)
Paul Tudor Jones Sold Out
Frank Sands 5,500,277 sh (-1.37%)
Chuck Royce 155,665 sh (-2.99%)
Ron Baron 22,219 sh (-81.93%)
» More
Q4 2015

MDSO Guru Trades in Q4 2015

Chuck Royce 155,665 sh (unchged)
Jim Simons Sold Out
Ron Baron Sold Out
Frank Sands 5,465,577 sh (-0.63%)
Columbia Wanger 1,861,230 sh (-4.83%)
» More
Q1 2016

MDSO Guru Trades in Q1 2016

Chuck Royce 188,165 sh (+20.88%)
Columbia Wanger 1,864,018 sh (+0.15%)
Frank Sands 4,140,933 sh (-24.24%)
» More
» Details

Insider Trades

Latest Guru Trades with MDSO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Application Software » Health Information Services
Compare:NAS:INOV, NAS:WBMD, NAS:HQY, NAS:PINC, NYSE:EVH, NAS:OMCL, NAS:ATHN, NYSE:VEEV, NAS:HSTM, NAS:QSII, NYSE:TDOC, NAS:CPSI, NYSE:IMPR, OTCPK:PMCUF, OTCPK:CRWRF, NYSE:EVDY, OTCPK:ACHI, OTCPK:SNBP, OTCPK:COGZF, OTCPK:OMCM » details
Traded in other countries:2M9.Germany,
Medidata Solutions Inc provides cloud-based solutions for life sciences. It offers products and services including Medidata Rave, Medidata CTMS, Medidata Designer, Medidata Insights, and Medidata Grants Manager.

Medidata Solutions Inc was incorporated in June 1999and reincorporated in the State of Delaware in May 2000. The Company is a provider of cloud-based solutions for clinical research in life sciences, designed to transform clinical development and increase the value of the customers' research investments. Medidata's solutions are designed to address the underlying requirements of clinical development, rather than just its current processes, to maximize the value of the overall research process. Its cloud-based solutions, metrics and services allow users to accurately and efficiently design clinical trials; manage and monitor ongoing trial activities; develop and administer trial budgets; capture, manage and report clinical trial data; plan and execute randomized subject allocation methodologies; manage and allocate clinical trial supplies; and view, track, and evaluate trial progress through easy-to-use, Internet-enabled platforms. The Company compete with firms such as Oracle, Perceptive Informatics and others offering products and services that compete with one or more of the solutions. It competes on the basis of several factors, including, breadth and depth of solution offerings; platform capabilities, including interoperability; ease of use of solutions and rates of user adoption; solution functionality and flexibility; analytics and benchmarking; speed and performance required to enable customers to access clinical trial data in real-time; product reliability and scalability; infrastructure accessibility and security; regulatory compliance; financial stability; commercial and technology partnerships; depth of expertise and quality of professional services and customer support on a global basis; and sales and marketing capabilities, including the ability to create and communicate operational value. The Company has registered trademarks and service marks in the United States and abroad, and filed applications for the registration of additional trademarks and service marks. The principal trademarks are "Medidata," "Medidata Clinical Cloud," "Medidata Patient Cloud," "Medidata CRO Contractor," "Medidata Designer," "Medidata Grants Manager," "Medidata Rave," "Medidata Balance," "Medidata Coder," and "Medidata Insights." It also holds several domain names, including the domain names "mdsol.com" and "medidatasolutions.com". The use of Company's software products, services and hosted solutions by customers engaged in clinical trials must be done in a manner that is compliant with a complex array of United States federal and state laws and regulations, including regulation by the Food and Drug Administration, as well as regulations and guidance issued by foreign governments and international non-governmental organizations.

Ratios

vs
industry
vs
history
P/E(ttm) 132.53
MDSO's P/E(ttm) is ranked lower than
91% of the 1361 Companies
in the Global Health Information Services industry.

( Industry Median: 23.78 vs. MDSO: 132.53 )
Ranked among companies with meaningful P/E(ttm) only.
MDSO' s P/E(ttm) Range Over the Past 10 Years
Min: 11.29  Med: 87.13 Max: 2129.13
Current: 132.53
11.29
2129.13
Forward P/E 53.76
MDSO's Forward P/E is ranked lower than
82% of the 353 Companies
in the Global Health Information Services industry.

( Industry Median: 21.51 vs. MDSO: 53.76 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 132.53
MDSO's PE(NRI) is ranked lower than
90% of the 1241 Companies
in the Global Health Information Services industry.

( Industry Median: 24.26 vs. MDSO: 132.53 )
Ranked among companies with meaningful PE(NRI) only.
MDSO' s PE(NRI) Range Over the Past 10 Years
Min: 11.06  Med: 86.04 Max: 2129.13
Current: 132.53
11.06
2129.13
Price/Owner Earnings (ttm) 717.90
MDSO's Price/Owner Earnings (ttm) is ranked lower than
98% of the 726 Companies
in the Global Health Information Services industry.

( Industry Median: 24.14 vs. MDSO: 717.90 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
MDSO' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 28.78  Med: 174.79 Max: 10780
Current: 717.9
28.78
10780
P/B 9.42
MDSO's P/B is ranked lower than
85% of the 1976 Companies
in the Global Health Information Services industry.

( Industry Median: 2.76 vs. MDSO: 9.42 )
Ranked among companies with meaningful P/B only.
MDSO' s P/B Range Over the Past 10 Years
Min: 4.53  Med: 9.80 Max: 29.12
Current: 9.42
4.53
29.12
P/S 7.23
MDSO's P/S is ranked lower than
82% of the 2022 Companies
in the Global Health Information Services industry.

( Industry Median: 2.24 vs. MDSO: 7.23 )
Ranked among companies with meaningful P/S only.
MDSO' s P/S Range Over the Past 10 Years
Min: 1.29  Med: 5.03 Max: 12.47
Current: 7.23
1.29
12.47
PFCF 49.22
MDSO's PFCF is ranked lower than
76% of the 743 Companies
in the Global Health Information Services industry.

( Industry Median: 24.11 vs. MDSO: 49.22 )
Ranked among companies with meaningful PFCF only.
MDSO' s PFCF Range Over the Past 10 Years
Min: 12.98  Med: 45.40 Max: 274.73
Current: 49.22
12.98
274.73
POCF 35.37
MDSO's POCF is ranked lower than
79% of the 946 Companies
in the Global Health Information Services industry.

( Industry Median: 17.33 vs. MDSO: 35.37 )
Ranked among companies with meaningful POCF only.
MDSO' s POCF Range Over the Past 10 Years
Min: 10.19  Med: 35.41 Max: 136.33
Current: 35.37
10.19
136.33
EV-to-EBIT 81.40
MDSO's EV-to-EBIT is ranked lower than
89% of the 1333 Companies
in the Global Health Information Services industry.

( Industry Median: 16.49 vs. MDSO: 81.40 )
Ranked among companies with meaningful EV-to-EBIT only.
MDSO' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.7  Med: 48.15 Max: 344.6
Current: 81.4
8.7
344.6
EV-to-EBITDA 61.51
MDSO's EV-to-EBITDA is ranked lower than
87% of the 1449 Companies
in the Global Health Information Services industry.

( Industry Median: 12.53 vs. MDSO: 61.51 )
Ranked among companies with meaningful EV-to-EBITDA only.
MDSO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.8  Med: 32.30 Max: 133.6
Current: 61.51
6.8
133.6
PEG 782.50
MDSO's PEG is ranked lower than
100% of the 553 Companies
in the Global Health Information Services industry.

( Industry Median: 9999.00 vs. MDSO: 782.50 )
Ranked among companies with meaningful PEG only.
MDSO' s PEG Range Over the Past 10 Years
Min: 8.16  Med: 17.16 Max: 100.47
Current: 782.5
8.16
100.47
Current Ratio 4.22
MDSO's Current Ratio is ranked higher than
82% of the 1711 Companies
in the Global Health Information Services industry.

( Industry Median: 1.94 vs. MDSO: 4.22 )
Ranked among companies with meaningful Current Ratio only.
MDSO' s Current Ratio Range Over the Past 10 Years
Min: 0.44  Med: 2.24 Max: 5.35
Current: 4.22
0.44
5.35
Quick Ratio 4.22
MDSO's Quick Ratio is ranked higher than
83% of the 1711 Companies
in the Global Health Information Services industry.

( Industry Median: 1.83 vs. MDSO: 4.22 )
Ranked among companies with meaningful Quick Ratio only.
MDSO' s Quick Ratio Range Over the Past 10 Years
Min: 0.44  Med: 2.24 Max: 5.35
Current: 4.22
0.44
5.35
Days Sales Outstanding 78.44
MDSO's Days Sales Outstanding is ranked lower than
60% of the 1493 Companies
in the Global Health Information Services industry.

( Industry Median: 68.62 vs. MDSO: 78.44 )
Ranked among companies with meaningful Days Sales Outstanding only.
MDSO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.45  Med: 74.59 Max: 90.9
Current: 78.44
45.45
90.9
Days Payable 5.21
MDSO's Days Payable is ranked lower than
93% of the 1346 Companies
in the Global Health Information Services industry.

( Industry Median: 43.98 vs. MDSO: 5.21 )
Ranked among companies with meaningful Days Payable only.
MDSO' s Days Payable Range Over the Past 10 Years
Min: 16.07  Med: 23.99 Max: 54.1
Current: 5.21
16.07
54.1

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 93.98
MDSO's Price/Net Current Asset Value is ranked lower than
97% of the 1360 Companies
in the Global Health Information Services industry.

( Industry Median: 6.62 vs. MDSO: 93.98 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
MDSO' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 8.65  Med: 18.79 Max: 4775
Current: 93.98
8.65
4775
Price/Tangible Book 10.64
MDSO's Price/Tangible Book is ranked lower than
77% of the 1667 Companies
in the Global Health Information Services industry.

( Industry Median: 4.20 vs. MDSO: 10.64 )
Ranked among companies with meaningful Price/Tangible Book only.
MDSO' s Price/Tangible Book Range Over the Past 10 Years
Min: 6.33  Med: 10.78 Max: 154.69
Current: 10.64
6.33
154.69
Price/Projected FCF 4.34
MDSO's Price/Projected FCF is ranked lower than
79% of the 929 Companies
in the Global Health Information Services industry.

( Industry Median: 1.75 vs. MDSO: 4.34 )
Ranked among companies with meaningful Price/Projected FCF only.
MDSO' s Price/Projected FCF Range Over the Past 10 Years
Min: 3.25  Med: 5.55 Max: 9.77
Current: 4.34
3.25
9.77
Price/Median PS Value 1.44
MDSO's Price/Median PS Value is ranked lower than
70% of the 1860 Companies
in the Global Health Information Services industry.

( Industry Median: 1.10 vs. MDSO: 1.44 )
Ranked among companies with meaningful Price/Median PS Value only.
MDSO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.26  Med: 0.95 Max: 2.33
Current: 1.44
0.26
2.33
Price/Graham Number 7.92
MDSO's Price/Graham Number is ranked lower than
91% of the 1041 Companies
in the Global Health Information Services industry.

( Industry Median: 2.10 vs. MDSO: 7.92 )
Ranked among companies with meaningful Price/Graham Number only.
MDSO' s Price/Graham Number Range Over the Past 10 Years
Min: 1.88  Med: 7.75 Max: 29.72
Current: 7.92
1.88
29.72
Earnings Yield (Greenblatt) (%) 1.20
MDSO's Earnings Yield (Greenblatt) (%) is ranked lower than
57% of the 2116 Companies
in the Global Health Information Services industry.

( Industry Median: 2.26 vs. MDSO: 1.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MDSO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.3  Med: 2.10 Max: 11.5
Current: 1.2
0.3
11.5
Forward Rate of Return (Yacktman) (%) -0.59
MDSO's Forward Rate of Return (Yacktman) (%) is ranked lower than
74% of the 726 Companies
in the Global Health Information Services industry.

( Industry Median: 10.04 vs. MDSO: -0.59 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MDSO' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -3.1  Med: 0.70 Max: 21.2
Current: -0.59
-3.1
21.2

More Statistics

Revenue (TTM) (Mil) $420.8
EPS (TTM) $ 0.39
Beta1.56
Short Percentage of Float11.69%
52-Week Range $30.22 - 54.99
Shares Outstanding (Mil)57.30

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $) 463 544 620
EPS ($) 1.00 1.29 1.47
EPS w/o NRI ($) 1.00 1.29 1.47
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for MDSO

Headlines

Articles On GuruFocus.com
There’s More In The Clouds At Medidata Than Just The Valuation Jul 21 2015 
Frank Sands Adds to His Position in Medidata Solutions, Inc. Jul 14 2015 
Medidata: SaaS Business Model Leveraging Growth Of The Company Oct 23 2014 
Frank Sands Adds 5 New Stocks Aug 14 2014 
Medidata Solutions: Benefit from Growing Cloud Applications with This Stock May 27 2014 
Medidata Solutions : A SAAS Provider For Your Portfolio Mar 23 2014 
Medidata Solutions Inc. (MDSO) Chairman & CEO Tarek Sherif sells 8,667 Shares Mar 08 2011 
Medidata Solutions Inc. (MDSO) Chairman & CEO Tarek Sherif sells 8,000 Shares Mar 03 2011 
Medidata Solutions Inc. (MDSO) Chairman & CEO Tarek Sherif sells 13,667 Shares Feb 07 2011 
Medidata Solutions Inc. (MDSO) Chairman & CEO Tarek Sherif sells 3,000 Shares Feb 03 2011 

More From Other Websites
8:30 am Medidata Solutions announces its cloud technology has been selected by Biogen (Jul 24 2016
Medidata Cloud Technology Selected to Support Biogen Clinical Trials Jul 22 2016
Medidata Cloud Technology Selected to Support Biogen Clinical Trials Jul 22 2016
Medidata (MDSO) Tops Q2 Earnings & Revenues, Shares Up Jul 21 2016
ETF’s with exposure to Medidata Solutions, Inc. : July 21, 2016 Jul 21 2016
Medidata Solutions, Inc. :MDSO-US: Earnings Analysis: Q2, 2016 By the Numbers : July 21, 2016 Jul 21 2016
Medidata Solutions downgraded by Wells Fargo Jul 21 2016
Edited Transcript of MDSO earnings conference call or presentation 20-Jul-16 12:00pm GMT Jul 20 2016
Here’s Why These Five Stocks Are on the Move on Wednesday Jul 20 2016
Dow, S&P Hit New Highs; Facebook Breaks Out; Microsoft, Intuitive Surgical Jump Jul 20 2016
Q2 2016 Medidata Solutions Inc Earnings Release - Before Market Open Jul 20 2016
Medidata tops Street 2Q forecasts Jul 20 2016
Medidata tops Street 2Q forecasts Jul 20 2016
MEDIDATA SOLUTIONS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 20 2016
Medidata Reports Record Second Quarter 2016 Results Jul 20 2016
Medidata Collaborates with Leading New York Cancer Center to Expand the Use of mHealth Technology in... Jul 19 2016
Medical Product Earnings on Jul 20: STJ, MDSO, BABY Jul 19 2016
Medidata's Payment Solution to Make Reimbursements Easy Jul 19 2016
Medidata Introduces New Payment Technology on its Unified Platform to Automate Reimbursements to... Jul 18 2016
ETF’s with exposure to Medidata Solutions, Inc. : July 6, 2016 Jul 06 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)